agoniste sérotoninergique et adrénergique, molécule neuroprotectrice, l'apomorphine se révèle donc d'un grand ,
Apomorphine in Dopaminergic Therapy, Molecular Pharmaceutics, vol.3, issue.4, pp.380-385, 2006. ,
DOI : 10.1021/mp060012c
Apomorphine and Levodopa Infusion Therapies for Advanced Parkinson???s Disease, Journal of Movement Disorders, vol.2, issue.1, pp.4-9, 2009. ,
DOI : 10.14802/jmd.09002
The pharmacology and clinical pharmacokinetics of apomorphine SL, BJU International, vol.24, pp.18-21, 2001. ,
DOI : 10.1046/j.1464-4096.2001.00124.x
Dopamine receptor agonists for Parkinson's disease, Expert Opinion on Investigational Drugs, vol.17, issue.2, pp.387-410, 2014. ,
DOI : 10.1124/jpet.102.039883
Practical considerations in the use of apomorphine injectable, Neurology, vol.62, issue.Issue 6, Supplement 4, pp.32-36, 2004. ,
DOI : 10.1212/WNL.62.6_suppl_4.S32
Role of Apomorphine in the Treatment of Parkinson???s Disease, CNS Drugs, vol.24, issue.8, pp.83-89, 2015. ,
DOI : 10.1007/s40263-014-0221-z
Nondopaminergic mechanisms in levodopa-induced dyskinesia, Movement Disorders, vol.5, issue.8, pp.919-931, 2005. ,
DOI : 10.1002/mds.20612
Relief of akinesia by apomorphine and cerebral metabolic changes in parkinson's disease, Movement Disorders, vol.7, issue.suppl 1, pp.459-462, 1993. ,
DOI : 10.1002/mds.870080407
Motor and nonmotor complications in Parkinson???s disease: an argument for continuous drug delivery?, Journal of Neural Transmission, vol.74, issue.Suppl 1, pp.1305-1320, 2013. ,
DOI : 10.1007/s00702-013-0981-5
A review of intermittent subcutaneous apomorphineinjections for the rescue management of motor fluctuations associated with advanced Parkinson's disease, Clinical Therapeutics, vol.27, issue.11, pp.1710-1724, 2005. ,
DOI : 10.1016/j.clinthera.2005.11.016
Contributions of central and systemic inflammation to the pathophysiology of Parkinson's disease, Neuropharmacology, vol.62, issue.7, pp.2154-2168, 2012. ,
DOI : 10.1016/j.neuropharm.2012.01.028
Clinical Usefulness of Apomorphine in Movement Disorders, Clinical Neuropharmacology, vol.17, issue.3, pp.243-259, 1994. ,
DOI : 10.1097/00002826-199406000-00004
Intrastriatal injection of D1 or D2 dopamine agonists affects glucose utilization in both the direct and indirect pathways of the rat basal ganglia, Neuroscience Letters, vol.309, issue.3, pp.161-164, 2001. ,
DOI : 10.1016/S0304-3940(01)02068-7
Subcutaneous Apomorphine, Drugs & Aging, vol.58, issue.11, pp.687-709, 2004. ,
DOI : 10.2165/00002512-200421110-00001
Apomorphine and the dopamine hypothesis of schizophrenia: a dilemma?, J Psychiatry Neurosci, vol.26, issue.3, pp.203-223, 2001. ,
L???apomorphine en perfusion sous-cutan??e continue dans le traitement de la maladie de Parkinson, Revue Neurologique, vol.162, issue.10, pp.10-1019, 2006. ,
DOI : 10.1016/S0035-3787(06)75115-3
Use of apomorphine in parkinsonian patients with neuropsychiatric complications to oral treatment, Parkinsonism & Related Disorders, vol.3, issue.2, pp.103-107, 1997. ,
DOI : 10.1016/S1353-8020(97)00009-6
Literature review: Intermittent subcutaneous apomorphine therapy in Parkinson's disease, Neurology, vol.62, issue.Issue 6, Supplement 4, pp.12-17, 2004. ,
DOI : 10.1212/WNL.62.6_suppl_4.S12
Absorption of apomorphine by various routes in parkinsonism, Movement Disorders, vol.1, issue.3, pp.212-216, 1991. ,
DOI : 10.1002/mds.870060304
New insights into the oxidation pathways of apomorphine, Journal of the Chemical Society, Perkin Transactions 2, issue.10, pp.1713-1717, 2002. ,
DOI : 10.1039/b204605a
Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction, European Journal of Pharmacology, vol.308, issue.2, pp.219-225, 1996. ,
DOI : 10.1016/0014-2999(96)00291-9
Apomorphine therapy in Parkinson's disease: a review, Expert Opinion on Pharmacotherapy, vol.62, issue.16, pp.2799-2809, 2007. ,
DOI : 10.1212/01.wnl.0000215250.82576.87
Apomorphine protects against 6-hydroxydopamine-induced neuronal cell death through activation of the Nrf2-ARE pathway, Journal of Neuroscience Research, vol.93, issue.4, pp.860-866, 2006. ,
DOI : 10.1002/jnr.20974
6500-004 Study Group. Sustained efficacy of apomorphine in Japanese patients with advanced Parkinson's Disease. Parkinsonism and related disorders, pp.819-823, 2014. ,
Clinical insights into use of apomorphine in Parkinson's disease: tools for clinicians, Neurodegenerative Disease Management, vol.4, issue.3, pp.271-282, 2014. ,
DOI : 10.2217/nmt.14.17
Apomorphine treatment in Alzheimer mice promoting amyloid-?? degradation, Annals of Neurology, vol.108, issue.2, pp.248-256, 2011. ,
DOI : 10.1002/ana.22319
Subcutaneous apomorphine in parkinson's disease: Response to chronic administration for up to five years, Movement Disorders, vol.4, issue.2, pp.165-170, 1993. ,
DOI : 10.1002/mds.870080208
Comparison of motor response to apomorphine and levodopa in Parkinson's disease., Journal of Neurology, Neurosurgery & Psychiatry, vol.53, issue.11, pp.1004-1007, 1990. ,
DOI : 10.1136/jnnp.53.11.1004
Other formulations and future considerations for apomorphine for subcutaneous injection therapy, Neurology, vol.62, issue.Issue 6, Supplement 4, pp.22-26, 2004. ,
DOI : 10.1212/WNL.62.6_suppl_4.S22
Dopamine agonists in Parkinson's disease: a look at apomorphine, Fundamental & Clinical Pharmacology, vol.ii, issue.3-4, pp.121-128, 1993. ,
DOI : 10.1111/j.1472-8206.1993.tb00226.x
Subcutaneously administered apomorphine: Pharmacokinetics and metabolism, Neurology, vol.62, issue.Issue 6, Supplement 4, pp.8-11, 2004. ,
DOI : 10.1212/WNL.62.6_suppl_4.S8
Neuronal recordings in Parkinson's disease patients with dyskinesias induced by apomorphine, Ann Neurol, vol.47, pp.141-146, 2000. ,
Intravenous apomorphine therapy in Parkinson's disease: Clinical and pharmacokinetic observations, Brain, vol.124, issue.2, pp.331-340, 2001. ,
DOI : 10.1093/brain/124.2.331
Apomorphine in the treatment of Parkinson's disease, Expert Opinion on Pharmacotherapy, vol.16, issue.12, pp.1941-1950, 2007. ,
DOI : 10.1002/mds.870130505
Apomorphine responses in parkinson's disease and the pathogenesis of motor complications, Neurology, vol.48, issue.2, pp.369-372, 1997. ,
DOI : 10.1212/WNL.48.2.369
Apomorphine-induced brain modulation during sexual stimulation: a new look at central phenomena related to erectile dysfunction, International Journal of Impotence Research, vol.15, issue.3, pp.203-209, 2003. ,
DOI : 10.1038/sj.ijir.3900999
Apomorphine in patients with Parkinson's disease, Biomedicine & Pharmacotherapy, vol.49, issue.4, pp.197-209, 1995. ,
DOI : 10.1016/0753-3322(96)82620-5
Pharmacokinetics of apomorphine in parkinsonian patients, Fundamental & Clinical Pharmacology, vol.i, issue.5, pp.245-252, 1993. ,
DOI : 10.1111/j.1472-8206.1993.tb00238.x
The rationale for continuous dopaminergic stimulation in advanced Parkinson's disease, Parkinsonism & Related Disorders, vol.13, pp.13-17, 2007. ,
DOI : 10.1016/j.parkreldis.2007.06.005
Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up, Journal of Neurology, Neurosurgery & Psychiatry, vol.65, issue.5, pp.709-716, 1998. ,
DOI : 10.1136/jnnp.65.5.709
Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson's disease, Parkinsonism & Related Disorders, vol.13, issue.2, pp.93-100, 2007. ,
DOI : 10.1016/j.parkreldis.2006.06.012
Apomorphine: An underutilized therapy for Parkinson's disease, Movement Disorders, vol.51, issue.5, pp.789-794, 2000. ,
DOI : 10.1002/1531-8257(200009)15:5<789::AID-MDS1005>3.0.CO;2-H
Le traitement par apomorphine en perfusion continue sous-cutan??e dans la maladie de Parkinson??: analyse r??trospective d???une s??rie de 81??patients, Revue Neurologique, vol.170, issue.3, pp.205-215, 2014. ,
DOI : 10.1016/j.neurol.2013.10.012
The Pharmacological Properties and Therapeutic Use of Apomorphine, Molecules, vol.17, issue.12, pp.5289-5309, 2012. ,
DOI : 10.3390/molecules17055289
Apomorphine induced cognitive changes in Parkinson's disease., Journal of Neurology, Neurosurgery & Psychiatry, vol.57, issue.8, pp.998-1001, 1994. ,
DOI : 10.1136/jnnp.57.8.998
Distribution of apomorphine enantiomers in plasma, brain tissue and striatal extracellular fluid, European Journal of Pharmacology, vol.329, issue.1, pp.9-15, 1997. ,
DOI : 10.1016/S0014-2999(97)10082-6
Dopamine receptor pharmacology, Trends in Pharmacological Sciences, vol.15, issue.7, pp.264-70, 1994. ,
DOI : 10.1016/0165-6147(94)90323-9
Apomorphine for the acute treatment of ???off??? episodes in Parkinson's disease, Parkinsonism & Related Disorders, vol.14, issue.2, pp.85-92, 2008. ,
DOI : 10.1016/j.parkreldis.2007.07.016
Apomorphine: North American clinical experience, Neurology, vol.62, issue.Issue 6, Supplement 4, pp.18-21, 2004. ,
DOI : 10.1212/WNL.62.6_suppl_4.S18
The clinical use of apomorphine in Parkinson's disease, J Neurol, vol.239, pp.389-393, 1992. ,
Continuous dopaminergic stimulation in early and advanced Parkinson's disease, Neurology, vol.62, issue.Issue 1, Supplement 1, pp.56-63, 2004. ,
DOI : 10.1212/WNL.62.1_suppl_1.S56
Review: Therapeutic options for continuous dopaminergic stimulation in Parkinson's disease, Therapeutic Advances in Neurological Disorders, vol.68, issue.1, pp.105-113, 2009. ,
DOI : 10.1177/1756285608101378
History of levodopa and dopamine agonists in Parkinson's disease treatment, Neurology, vol.50, issue.Issue 6, Supplement 6, pp.2-10, 1998. ,
DOI : 10.1212/WNL.50.6_Suppl_6.S2
on behalf of an Expert Consensus Group for the Use of Apomorphine in Parkinson's Disease, Expert consensus group report on the use of apomorphine in the treatment of Parkinson's disease-Clinical practice recommendations, pp.1023-1030, 2015. ,
A 10 year retrospective audit of long-term apomorphine use in Parkinson?s disease, Journal of Neurology, vol.48, issue.11, pp.1370-1374, 2004. ,
DOI : 10.1007/s00415-004-0547-4
Apomorphine offers new insight into dopaminergic neuron vulnerability in mesencephalic cultures, Neuropharmacology, vol.55, issue.5, pp.737-742, 2008. ,
DOI : 10.1016/j.neuropharm.2008.06.041
Assay of R-apomorphine, S-apomorphine, apocodeine, isoapocodeine and their glucuronide and sulfat conjugates in plasma and urine of patients with Parkinson's disease, Journal of Chromatography B, pp.702-131, 1997. ,
The role of EDTA in provoking allergic reactions to subcutaneous infusion of apomorphine in patients with Parkinson's disease: A histologic study, Movement Disorders, vol.1, issue.1, pp.52-55, 1998. ,
DOI : 10.1002/mds.870130113
Agonist and antagonist effects of apomorphine enantiomers on 5-HT3 receptors, Neuropharmacology, vol.37, issue.2, pp.259-264, 1998. ,
DOI : 10.1016/S0028-3908(98)00044-6
Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson???s disease in the UK and Germany, Journal of Medical Economics, vol.18, issue.2, pp.155-65, 2015. ,
DOI : 10.3111/13696998.2014.979937
The role of subcutaneous infusion of apomorphine in Parkinson???s disease, Expert Review of Neurotherapeutics, vol.14, issue.7, pp.833-843, 2014. ,
DOI : 10.1586/14737175.2014.928202
Doin, Collection conduites, France. 209 pages, p.2, 2006. ,
Safety of entacapone and apomorphine coadministration in levodopa-treated Parkinson's disease patients: Pharmacokinetic and pharmacodynamic results of a multicenter, double-blind, placebo-controlled, cross-over study, Movement Disorders, vol.8, issue.9, pp.1006-1011, 2004. ,
DOI : 10.1002/mds.20188